International Patient-Physician Summit on Waldenstrom’s macroglobulinemia
Lia Palomba M.D., Memorial Sloan Kettering Cancer Center, New York NY, USA
Richard Furman, M.D., Weill Cornell Medical Center, New York NY, USA
Jorge J. Castillo, M.D., Dana Farber Cancer Institute, Boston MA, USA
Steven P. Treon MD, PhD, Dana Farber Cancer Institute, Boston MA, USA
Saturday, October 13, 2018
7:00am Registration and Coffee service
Session I - Genomics in the Diagnosis and Management of WM
Chairs: Ramon Garcia Sanz (Spain) and Jorge Castillo (USA)
8:00am - How important is getting MYD88 mutation status for the diagnosis of WM?
How and when should MYD88 and CXCR4 mutation be evaluated?
8:20am - Can MYD88 mutation status impact overall survival in WM?
How can CXCR4 mutation status be used in the management of the WM patient?
8:40am - Chair Discussion for Session I
Session II - Predisposition to WM
Chairs: Mary McMaster (USA) and Ola Landgren (USA)
9:00am - What IgM MGUS and smoldering WM patients are at risk for progression to active WM?
Is detection of mutated MYD88 associated with progression of IGM MGUS?
9:20am - What genomic changes accompany transition of IgM MGUS to WM?
What underlying genomics are responsible for familial WM?
Is Agent Orange exposure associated with WM?
9:40am - Chair Discussion for Session II
10:30am - Morning Refreshments
Session III - Disease Presentation in WM
Shirley D’SA (UK) and Monique Minnema (Netherlands)
11:00am - How should patients with WM related peripheral neuropathy be evaluated?
What is the spectrum of presentation associated with anti-MAG antibodies?
11:20am - How should patients with Bing Neel Syndrome be evaluated?
When should plasmapheresis be used in the management of WM?
11:40am - Chair Discussion for Session III
Session IVGenomic Landscape of WM
Zachary Hunter (USA) and Marzia Varretoni (Italy)
1:00pm - What are the important genomic findings in WM?
How important are TP53 mutations in WM?
1:20pm - What are the treatment implications for mutations found in WM?
What mutations accompany disease transformation in WM?
Are losses in 6q important to WM growth and survival?
1:40pm - Chair Discussion for Session IV
Session V - Mechanisms of Tumor Growth and Survival in WM
Steve Treon (USA) and ST Pals (Netherlands)
2:00pm - How do MYD88 mutations impact WM cell growth and survival?
Do exosomes play a role in propagating mutated MYD88 signaling?
2:20pm - Are MYD88 mutations by themselves sufficient to cause WM?
Do genomics impact cytokine related signaling in WM?
How does the microenvironment impact WM cell growth and drug resistance?
2:40pm - Chair Discussion for Session V
3:00pm - Afternoon Refreshments
Session VI - Clinical Trials in WM: Rituximab-based therapy
Véronique LeBlond (France) and Matthias Rummel (Germany)
3:30pm - Bendamustine and Rituximab in treatment naïve patients with WM
Rituximab Maintenance versus Observation following Bendamustine-Rituximab in WM
3:50pm - Long term efficacy of Rituximab in MAG positive peripheral neuropathy RIMAG study follow-up
Randomized clinical trial of BCR vs. FCR in treatment naïve WM patients
4:10pm - Chair Discussion for Session VI
4:30pm - Day Highlights & Adjournment
Sunday, October 14, 2018
7:30am - Registration and Coffee service
Session VIIClinical Trial Updates in WM: Proteasome Inhibitors
Stathis Kastritis (Greece) and MJ Kersten (Netherlands)
8:00am - Long term follow-up of Bortezomib, Dexamethasone and Rituximab in treatment-naïve WM
Long term follow-up of Carfilzomib, Dexamethasone and Rituximab in treatment-naïve WM
8:20am - Prospective study of Carfilzomib in previously treated WM patients
Prospective Study of Ixazomib, Dexamethasone, Rituximab in previously-treated WM patients
8:40am - Chair Discussion for Session VII
Session VIII - Clinical Trials Updates in WM: Ibrutinib
Lia Palomba (USA) and Meletios Dimopoulos (Greece)
9:00am - Ibrutinib monotherapy in treatment-naïve WM patients
Long term follow-up of ibrutinib monotherapy in previously-treated WM patients:
Update of pivotal trial
9:20am - Ibrutinib monotherapy in rituximab-refractory WM patients
Randomized clinical trial of ibrutinib/rituximab versus rituximab in symptomatic WM patients
9:40am - Chair Discussion on Session VIII
10:00am - Morning Refreshments
Session IX - Clinical Trials Updates in WM: Novel Agents
Judith Trotman (Australia) and Jorge Castillo (USA)
10:30am - Phase II Study of the BTK-inhibitor Acalabrutinib in previously-treated WM patients
Phase II Study of the BTK-inhibitor Zanubrutinib in symptomatic WM patients
10:50am - Phase II Study of the BCL2-inhibitor Venetoclax in previously treated WM patients
Phase I/II Study of the CXCR4-inhibitor Ulocuplomab plus ibrutinib in symptomatic WM patients
Phase II Study of the CD38-antibody Daratumumab in previously treated WM patients
11:15am - Chair Discussion on Session IX
Session X - Ibrutinib Resistance in WM
Richard Furman (USA) and Adrian Wiestner (USA)
11:30am - What mutations are associated with resistance to BTK-inhibitors in WM?
What are the mechanisms of resistance to ibrutinib in WM?
11:50am - Evolutional Landscape of Ibrutinib Resistance
Understanding and overcoming ibrutinib resistance in B-cell malignancies
12:10pm - Panel Discussion on Session X
12:30pm - LUNCH
Session XI - Associated and Secondary Malignancy Risks in WM Patients
Alessandra Tedeschi (Italy) and Stathis Kastritis (Greece)
1:30pm - Are WM patients at higher risk for treatment unrelated cancers?
How important are treatment related secondary malignancies in WM?
1:50pm - Are there risk factors that predict for disease transformation in WM?
Should additional cancer screening measures be adopted for WM patients?
2:10pm - Chair Discussion on Session XI
2:30pm - Afternoon Refreshments
Session XII - Case Presentations in WM
Lia Palomba (USA) and Rick Furman (USA), Moderators
3:00pm - Case Presentations (4)
4:30pm - Day Highlights & Adjournment